Hjem › Crohns sygdom › Arizona
Crohns sygdom kliniske forsøg i Arizona
17 studier for Crohns sygdom søger deltagere på steder i Arizona.
Byer i Arizona
Officiel studietekst (engelsk)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- GI Alliance - Sun City ( Site 5118), Sun City
- University of Arizona Clinical and Translational Sciences Research Center ( Site 5111), Tucson
RekruttererFase 3
Alder 16 til 80 · Alle køn · Opdateret 2. okt. 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Elite Clinical Studies /ID# 280477, Phoenix
- Gi Alliance - Arizona Digestive Health - Sun City /ID# 284084, Sun City
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- AZ Gastro Care, Chandler
- Spectrum Research Institute LLC, Gilbert
- GI Alliance- Sun City, Sun City
RekruttererFase 4
Alder 18 til 80 · Alle køn · Opdateret 30. sep. 2026 · NCT06581328A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- AZ Gastro Care, Chandler
- Research Solutions of Arizona, Litchfield Park
- Mayo Clinic, Scottsdale
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07196722An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Onyx Clinical Research - Site Number:8400021, Peoria
- One of a Kind Clinical Research Center AZ, LLC-Site Number: 8400061, Scottsdale
- Scottsdale Clinical Trials-Site Number: 8400145, Scottsdale
- og 1 flere
RekruttererFase 3
Alder 16 til 80 · Alle køn · Opdateret 23. sep. 2026 · NCT07184931A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Phoenix Children's Hospital /ID# 255766, Phoenix
RekruttererFase 3
Alder 2 til 17 · Alle køn · Opdateret 23. sep. 2026 · NCT05995353A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- GI Alliance Sun City, Sun City
RekruttererFase 4
Alder 18 til 70 · Alle køn · Opdateret 9. sep. 2026 · NCT06045754Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- Mayo Clinic Arizona, Scottsdale
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 7. aug. 2026 · NCT05230173A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
- Phoenix Children's Hospital, Phoenix
RekruttererFase 3
Alder 2 til 17 · Alle køn · Opdateret 3. aug. 2026 · NCT06100289A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Phoenix Childrens Hospital, Phoenix
RekruttererFase 3
Alder 2 til 17 · Alle køn · Opdateret 22. jun. 2026 · NCT06405087Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Phoenix Children's Hospital, Phoenix
RekruttererFase 4
Alder 6 til 17 · Alle køn · Opdateret 27. maj 2026 · NCT05781152A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Phoenix Childrens Hospital - Thomas Rd - PIN, Phoenix
RekruttererFase 3
Alder 2 og opefter · Alle køn · Opdateret 7. maj 2026 · NCT05442567A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Phoenix Childrens Hospital, Phoenix
RekruttererFase 3
Alder 2 til 17 · Alle køn · Opdateret 5. maj 2026 · NCT04779320Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- Scottsdale Gastroenterology Specialists, Scottsdale
- GI Alliance -Gurnee, Sun City
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 27. apr. 2026 · NCT06456593A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
- Investigational Site Number: 8400024, Tucson
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 27. mar. 2026 · NCT06958536A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Scottsdale
- Mirador Therapeutics Selected Site, Sun City
RekruttererFase 2
Alder 18 til 80 · Alle køn · Opdateret 12. mar. 2026 · NCT07113522Treatment of Moderate to Severe Refractory Crohn's Disease
- Mayo Clinic Arizona, Scottsdale
RekruttererFase 1/2
Alder 18 til 65 · Alle køn · Opdateret 10. dec. 2025 · NCT06721962Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.